Apollo Care, LLC
Has Apollo Care, LLC received an FDA warning letter about GLP-1 drugs?
No FDA warning letter to Apollo Care, LLC naming a GLP-1 drug appears in FDA’s posted letters as of Nov 15, 2026. The company is listed here because openFDA has 11 drug recall reports for it naming semaglutide, the latest initiated Jul 29, 2026.
FDA records in this index name Apollo Care, LLC on Jul 29, 2026.
- Type named in FDA records
- Not stated
- FDA warning letters
- 0
- Drug recall reports
- 11
- Drugs named
- Semaglutide
- Latest record
- Jul 29, 2026
FDA warning letters
No FDA warning letters in this index.
Drug recalls
| Record | |||||
|---|---|---|---|---|---|
| Jul 29, 2026 | SEMAGLUTIDE 7.5mg (5mg/mL), Glycine 7.5 mg (5mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, S... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0755-2026 |
| Jul 29, 2026 | SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 652... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0747-2026 |
| Jul 29, 2026 | SEMAGLUTIDE 2.25MG (0.9 mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO ... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0748-2026 |
| Jul 29, 2026 | SEMAGLUTIDE 2.5mg (1mg/mL), Glycine 12.5 mg (5mg/mL), 2.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801Mojave Ct, S... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0753-2026 |
| Jul 29, 2026 | SEMAGLUTIDE 6.75mg (4.5 mg/mL), 1.5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO ... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0749-2026 |
| Jul 29, 2026 | SEMAGLUTIDE 0.9mg (0.9 mg/mL), 1 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 652... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0752-2026 |
| Jul 29, 2026 | SEMAGLUTIDE 20mg (5mg/mL), Glycine 20 mg (5mg/mL), 4 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 1... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0757-2026 |
| Jul 29, 2026 | SEMAGLUTIDE 10mg (5mg/mL), Glycine 10 mg (5mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 1... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0756-2026 |
| Jul 29, 2026 | SEMAGLUTIDE 9mg (4.5 mg/mL), 2 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 65202... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0751-2026 |
| Jul 29, 2026 | SEMAGLUTIDE 4.5mg (0.9 mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 102, Columbia, MO 652... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0750-2026 |
| Jul 29, 2026 | SEMAGLUTIDE 5mg (1mg/mL), Glycine 25 mg (5mg/mL), 5 mL Sterile Multi-Dose Vial, Rx Only, For Subcutaneous Injection Only, APOLLO care, 3801 Mojave Ct, Ste 10... | Presence of Particulate Matter; identified as a nylon/polyamide and silk/proteinaceous-type material | Class II | Ongoing | D-0754-2026 |
FDA compounding inspections and actions
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists one facility under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.
Apollo Care LLC, Columbia, MO (503B)
7 listed actions, including 4 Form 483s and 2 warning letters (2019 to 2026).
| Document | |||
|---|---|---|---|
| Jul 28, 2026 | Form 483 | 483 Issued 07/28/2026 | fda.gov |
| Feb 2, 2026 | Warning letter | Warning Letter (02/02/2026) | fda.gov |
| Mar 27, 2025 | Form 483 | 483 Issued 03/27/2025 | fda.gov |
| Nov 27, 2023 | Regulatory meeting | Regulatory Meeting Held 11/27/2023 | Not linked by FDA |
| Apr 5, 2023 | Form 483 | 483 Issued 04/05/2023 | FDA copy (archived) |
| Sep 8, 2021 | Form 483 | 483 Issued 09/8/2021 | FDA copy (archived) |
| Mar 20, 2019 | Warning letter | Warning Letter (03/20/2019) | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Apollo Care LLC, Columbia, MO.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 8 products naming semaglutide and tirzepatide under the labeler name “Apollo Care, LLC”, matched to this company page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (8). The compounded product reports cover FDA reporting periods 2024-2 to 2026-1.
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 71170-495 | Semaglutide 12.5 mg | Semaglutide 12.5 mg | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 | Compounded drugs |
| 71170-640 | Semaglutide 1mg and Cyanocobalamin 0.5mg | Semaglutide 1mg and Cyanocobalamin 0.5mg | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mL; .5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 | Compounded drugs |
| 71170-650 | Semaglutide 2.5mg and Cyanocobalamin 0.5mg | Semaglutide 2.5mg and Cyanocobalamin 0.5mg | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL; .5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 | Compounded drugs |
| 71170-690 | Semaglutide 12.5mg and Cyanocobalamin 2.5mg | Semaglutide 12.5mg and Cyanocobalamin 2.5mg | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL; .5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 | Compounded drugs |
| 71170-811 | Semaglutide 2.25 mg | Semaglutide 2.25 mg | INJECTION, SOLUTION | SUBCUTANEOUS | .9 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 | Compounded drugs |
| 71170-821 | Semaglutide 6.75 mg | Semaglutide 6.75 mg | INJECTION, SOLUTION | SUBCUTANEOUS | 4.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-2, 2026-1 | Compounded drugs |
| 71170-610 | Tirzepatide 20mg and Pyridoxine 8mg | Tirzepatide 20mg and Pyridoxine 8mg | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/1 mL; 4 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 | Compounded drugs |
| 71170-630 | Tirzepatide 60mg and Pyridoxine 12mg | Tirzepatide 60mg and Pyridoxine 12mg | INJECTION, SOLUTION | SUBCUTANEOUS | 20 mg/1 mL; 4 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2024-2 | Compounded drugs |
FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- openFDA drug recall enforcement reports
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA warning letters (fda.gov full-text search)
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.